Antiplatelet and Antithrombotic Therapy in Type I Diabetes Mellitus: Update on Current Data

Curr Diabetes Rev. 2022;18(9):e030122199792. doi: 10.2174/1573399818666220103091236.

Abstract

Diabetes mellitus type 1 (T1DM) is an autoimmune disease characterized by a markedly elevated cardiovascular (CV) risk due to premature atherosclerosis. Previous studies have shown that intense glycemic control reduces the incidence of CV disease. Antiplatelet therapy is considered to be a very important therapy for secondary prevention of recurrent atherothrombotic events in patients with DM, while it may be considered for primary prevention in individuals with T1DM with additional CV risk factors. The aim of the present review is to summarize existing literature data regarding the thrombotic risk in T1DM patients and discuss current treatment strategies.

Keywords: LDL.; Type1 diabetes mellitus; antiplatelet therapy; antithrombotic therapy; cardiovascular disease; venous thromboembolism.

Publication types

  • Review

MeSH terms

  • Atherosclerosis* / drug therapy
  • Atherosclerosis* / prevention & control
  • Cardiovascular Diseases* / epidemiology
  • Cardiovascular Diseases* / etiology
  • Cardiovascular Diseases* / prevention & control
  • Diabetes Mellitus, Type 1* / complications
  • Diabetes Mellitus, Type 1* / drug therapy
  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Platelet Aggregation Inhibitors / therapeutic use
  • Secondary Prevention

Substances

  • Fibrinolytic Agents
  • Platelet Aggregation Inhibitors